1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Hickey, E. R. et al

Art Unit:

Serial No.:

10/790,549

Examiner:

Conf. No.:

9699

Filed:

03/01/2004

For:

Cathepsin S Inhibitors

Docket No.:

9/278

Office of Initial Patent Examination's Customer Service Center Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Via Facsimile: 703/746-9195

Page 1 of 7 Pages

November 12, 2004

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The undersigned respectfully requests correction of the Filing Receipt for Application Number 10/790,549, Confirmation No. 9699.

Please correct the spelling of the first name of the second named applicant from "Wiemen" to -Weimin-, as noted on the attached copy of the Official Filing Receipt and Supplemental Application Data Sheet.

The undersigned hereby requests that the United States Patent and Trademark Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Anthony P. Bottino

Attorney for Applicant(s)

mel Callo

Reg. No. 41,629

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6764

Tel: (203) 791-6764

Date: November 12, 2004


Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to 703/746-9195 addressed to:

Office of Initial Patent Examination Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

On November 12, 2004.

Anthony P. Bottino, Reg. No. 41,629



1614

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Tradomark Office Address COMMISSIONER FOR PATENTS

m 22513-1450

DRAWINGS

TOT CLMS IND CLMS

CONFIRMATION NO. 9699

28509 BOEHRINGER INGELHEIM CORPORATION 900 RIDGEBURY ROAD

03/01/2004

P O BOX 368 RIDGEFIELD, CT 06877

10/790.549

FILING RECEIPT OC000000012787282*

Date Mailed: 05/27/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

ATTY.DOCKET NO

9/278

Applicant(s)

Eugene R. Hickey, Danbury, CT; Wiemen Liu, Sandy Hook, CT; Weimin-Sanxing Sun, Danbury, CT; Yancey David Ward, Sandy Hook, CT;

Erick Richard Roush Young, Danbury, CT;

Assignment For Published Patent Application

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT;

1146

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/454,239 03/13/2003

Foreign Applications

If Required, Foreign Filing License Granted: 05/25/2004

Projected Publication Date: 09/16/2004

Non-Publication Request: No

Early Publication Request: No

JUN - 2 2004

BEST AVAILABLE COPY

Title

Cathepsin 5 inhibitors

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

BEST AVAILABLE COPY